Organization
Irvine, CA
5 abstracts
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
Expression of alternatively spliced BCMA RNA with skipping of transmembrane domain.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack, NJ, Genomic Testing Cooperative, Irvine, CA, Irvine, CA, Hackensack University Medical Center,
Abstract
Distinguishing between cancer-related mutations and clonal hematopoiesis using cell-free RNA (cfRNA) expression levels in a machine learning model.Org: Genomic Testing Cooperative, Irvine, CA, Irvine, CA, Genomics Testing Cooperative, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack, NJ,
Abstract
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.Org: Institut de Cancérologie Gustave Roussy, Villejuif, France, France, Perlmutter Cancer Center at NYU Langone Health Medical Center, New York, NY,
Abstract
Integration of breast-oncology clinical pathways in Providence Southern California clinical research network.Org: Saint John’s Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, Providence California Regional Services, Irvine, CA, Providence Health and Services,